

Grazoprevir (MK-5172)

ALTERNATE NAME: MK-5172

(33R,35S,91R,92R,5S)-5-(tert-butyl)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-

17-methoxy-4,7-dioxo-2,8-dioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-

cyclopropanacyclotetradecaphane-35-carboxamide

CATALOG #: B2337-25

B2337-5

AMOUNT: 25 mg 5 mg

STRUCTURE:

MOLECULAR FORMULA: $C_{3\ 8}\ H_{5\ 0}\ N_{6}\ O_{9}\ S$

MOLECULAR WEIGHT: 766.91

CAS NUMBER: 1350514-68-9

APPEARANCE: White to off-white solid

PURITY: ≥98% by HPLC

SOLUBILITY: >25 mg/ml (DMSO)

REFERENCES: Summa, V., et al. (2012). Antimicrob. Agents Chemother. 56(8), 4161-4167

DESCRIPTION: Grazoprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic

Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). Grazoprevir is a second-generation hepatitis C virus protease inhibitor acting at the NS3/4a protease targets. It has good activity against a range of HCV genotype variants, including some that are resistant to most

currently used antiviral medications.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of

exposure.

RELATED PRODUCTS:

Ribavirin (2199) Ritonavir (B2140) Oseltamivir acid (B1886) Telaprevir (B1235) Saquinavir mesylate (B1999) Danoprevir (B2184) Zanamivir (B1900) Velpatsavir (B1194) Oseltamivir Phosphate (B1885) Simeprevir (B1173)

DISCLAIMER: FOR RESEARCH USE ONLY! Not to be used on humans.